NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
Next-generation adenovirus-vectored anti-cancer vaccines make appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research.
Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
